Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1967 3
1968 1
1969 1
1971 1
1972 7
1973 2
1974 2
1975 1
1976 3
1977 4
1979 4
1980 1
1981 1
1982 13
1983 511
1984 1613
1985 1849
1986 1864
1987 1890
1988 2055
1989 2286
1990 2469
1991 2340
1992 2401
1993 2568
1994 2525
1995 2655
1996 2708
1997 2673
1998 2731
1999 2862
2000 3153
2001 3189
2002 3495
2003 3756
2004 3942
2005 4269
2006 4606
2007 4514
2008 4809
2009 5061
2010 5832
2011 5994
2012 6133
2013 6243
2014 6692
2015 6852
2016 6236
2017 5881
2018 5704
2019 2640
2020 75
Text availability
Article attribute
Article type
Publication date

Search Results

126,107 results
Results by year
Filters applied: . Clear all
Page 1
Combination immunotherapy: a road map
Ott PA, et al. J Immunother Cancer 2017 - Review. PMID 28239469 Free PMC article.
Initial evidence, for example with combined inhibition of PD-1 and CTLA-4 in melanoma and non-small cell lung cancer (NSCLC), has highlighted the potential to further enhance the clinical benefits of monotherapies by combining agents with synergistic mechanisms of action. ...As a result of the extensive clinical benefit and tolerable side effects demonstrated with agents inhibiting the PD-1 pathway, an overview of current evidence to support its promising potential for use as a backbone in combination strategies is presented. ...
Initial evidence, for example with combined inhibition of PD-1 and CTLA-4 in melanoma and non-small cell lung cancer (NSCLC), has hig …
Steroid-induced mental disorders in cancer patients: a systematic review
Ismail MF, et al. Future Oncol 2017 - Review. PMID 29186986
Neuropsychiatric toxicity has complicated their use, including an association with a spectrum of symptoms, from insomnia, cognitive impairment and mood symptoms, to severe mental disorders, including mania, psychosis and severe depression. ...We completed a systematic review of the current evidence for therapeutic and prophylactic interventions of steroid-induced mental disorders in cancer. ...
Neuropsychiatric toxicity has complicated their use, including an association with a spectrum of symptoms, from insomnia, cognitive i …
Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review.
Lyman GH, et al. Crit Rev Oncol Hematol 2014 - Review. PMID 24434034
Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of myelosuppressive chemotherapy that usually results in hospitalization and the need for intravenous antibiotics. FN may result in dose reductions, delays, or even discontinuation of chemotherapy, which, in turn, may compromise patient outcomes. ...
Neutropenia with fever (febrile neutropenia [FN]) is a serious consequence of myelosuppressive chemotherapy that usually results in h …
Systemic therapy for osteosarcoma and Ewing sarcoma
Meyers PA. Am Soc Clin Oncol Educ Book 2015 - Review. PMID 25993235 Free article.
Addition of liposomal muramyl tripeptide to chemotherapy may improve overall survival. Systemic therapy for Ewing sarcoma consists of multiagent chemotherapy including doxorubicin, vincristine, etoposide, and cyclophosphamide and/or ifosfamide. Increased dose intensity of therapy, either by shortening the intervals between cycles of chemotherapy or by increasing doses of chemotherapy, improves outcome. ...
Addition of liposomal muramyl tripeptide to chemotherapy may improve overall survival. Systemic therapy for Ewing sarcoma consists of …
Current Standards of Chemotherapy for Pancreatic Cancer.
Saung MT and Zheng L. Clin Ther 2017 - Review. PMID 28939405 Free PMC article.
FINDINGS: Although combination chemotherapy regimens are shown to be superior to gemcitabine monotherapy for both metastatic pancreatic cancer and adjuvant chemotherapy after surgical resection, it should be recognized that all combination chemotherapy regimens offer only limited benefits. In addition, there is a paucity of clinical trials that directly compare the various combination chemotherapy regimens. IMPLICATIONS: With the advancement of systemic cancer treatment beyond chemotherapy, it is important to devote more investigation into better understanding the biology of these chemotherapy regimens, such that we combine them with targeted therapeutics and immunotherapeutics in a rational and scientific manner. ...
FINDINGS: Although combination chemotherapy regimens are shown to be superior to gemcitabine monotherapy for both metastatic pancreat …
Metronomic Chemotherapy: Direct Targeting of Cancer Cells after all?
André N, et al. Trends Cancer 2017 - Review. PMID 28718409
Metronomic chemotherapy (MC) was initially described as an antiangiogenic therapy more than 15 years ago. Over the past few years, additional data have highlighted the impact of MC on the microenvironment beyond angiogenesis, with, most importantly, a potential impact on the immune system. ...
Metronomic chemotherapy (MC) was initially described as an antiangiogenic therapy more than 15 years ago. Over the past few years, ad …
Chemotherapy.
Pinedo HM and Giaccone G. Lancet 1997 - Review. PMID 9164439
The dose-dense principle in chemotherapy.
López ÁG, et al. J Theor Biol 2017. PMID 28689890
Chemotherapy is a cancer treatment modality that uses drugs to kill tumor cells. A typical chemotherapeutic protocol consists of several drugs delivered in cycles of three weeks. ...Our results suggest that there are compelling arguments supporting the use of dose-dense protocols. Finally, we discuss the limitations of these protocols and suggest an alternative....
Chemotherapy is a cancer treatment modality that uses drugs to kill tumor cells. A typical chemotherapeutic protocol consists
126,107 results
Jump to page
Feedback